Jacobs Levy Equity Management
CAPR icon

Jacobs Levy Equity Management’s Capricor Therapeutics CAPR Stock Holding History

Jacobs Levy Equity Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,173
Closed -$209K – 937
2017
Q1 		$209K Buy
+6,173
New +$171K ﹤0.01% 789

Other funds holding CAPR

CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AA
Apriem Advisors Irvine, California $1.05B AUM 22.09% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Jacobs Levy Equity Management's CAPR Position: Q2 2017 in Review

Jacobs Levy Equity Management sold out of Capricor Therapeutics (CAPR) in Q2 2017, closing a stake of 6,173 shares — an estimated $209K sold.

Jacobs Levy Equity Management first reported a position in CAPR in Q1 2017 and held it in 1 quarter. The position peaked at $209K in Q1 2017. 18 funds tracked by Wall St. Rank hold CAPR as of Q2 2017.

  • Jacobs Levy Equity Management reported no remaining Capricor Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 6,173 Capricor Therapeutics shares in Q2 2017, an estimated $209K.
  • Jacobs Levy Equity Management first reported a position in Capricor Therapeutics in Q1 2017 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Capricor Therapeutics position peaked at $209K in Q1 2017.
  • 18 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2017.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2017, filed 14 Aug 2017.